（记者 曾健辉） 每经头条（nbdtoutiao）——检查糖尿病却查出胰腺癌！仅凭百元CT揪出"癌症之王"，医生没看出来的 病，AI是怎么发现的？ 每经AI快讯，北投科技1月23日晚间发布公告称，公司第六届第二十次董事会会议于2026年1月23日以 通讯方式召开。会议审议了《关于预计2026年日常关联交易的议案》等文件。 ...

Group 1 - The company approved the temporary use of idle raised funds not exceeding 830 million yuan to supplement working capital related to its main business, with a usage period of no more than 12 months from the board's approval date [12][14][16] - The company raised a total of approximately 1.827 billion yuan through a non-public offering of shares, with a net amount of about 1.814 billion yuan after deducting issuance costs [14][16] - The board meeting held on January 22, 2026, was attended by all eight directors, and the resolutions were passed with unanimous consent [3][10] Group 2 - The company estimated the amount of daily related transactions for 2026, which was reviewed and approved by the independent directors before being submitted to the board [22][24] - The board meeting on January 22, 2026, approved the expected daily related transaction amounts, with certain directors recusing themselves from the vote [21][22] - The company confirmed that the daily related transactions would not adversely affect its normal business operations or the interests of shareholders, particularly minority shareholders [29][30]

Group 1 - The company held its 22nd meeting of the 9th Board of Directors on January 22, 2026, via telecommunication, with all 9 directors present, and the meeting was chaired by Chairman Chen Zhijian [2][3] - The Board approved the proposal regarding the expected daily related transactions for January-February 2026, which will involve a maximum amount of 22.19 million yuan [9][10] - The independent directors reviewed and approved the proposal, stating that the expected transactions are necessary for the company's operations and will not adversely affect its independence or harm the interests of shareholders [10][21] Group 2 - The expected daily related transactions will occur with Hebei Yanuo Biotechnology Group Co., Ltd. and its subsidiaries, which are controlled by the current director Liu Xiaomin [8][19] - The transactions are based on market prices and adhere to fair pricing principles, ensuring that they do not harm the company's interests [21][23] - The company has a good credit status and a history of fulfilling obligations in past transactions with the related parties [20]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002783 证券简称：凯龙股份 公告编号：2026－003 湖北凯龙化工集团股份有限公司 关于2026年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、公司日常关联交易基本情况 (一)日常关联交易概述 公司与关联方之间的关联交易将遵循平等自愿、公平合理、价格公允的原则，切实维护本公司及无关联 关系股东的合法权益。 (二)预计2026年日常关联交易类别和金额 单位：人民币万元 ■ 注： 1．鉴于公司2026年初至披露时，公司与上述关联方已发生的日常关联交易金额不大（预计与单个关联 方的交易不超过上一年度经审计净资产0.5%的披露标准）且统计困难，董事会提请股东会对2026年初 至披露时与上述关联方已发生的关联交易事项予以确认。 2．2025年发生金额为未经审计数据。 为保证湖北凯龙化工集团股份有限公司(以下简称"公司")正常开展生产经营活动，公司预计2026年度将 主要与下述单位发生日常关联交易： 1．公司(含分子公司)与湖北联兴民爆器材经营股份有限公司(以下简称"湖北联 ...

Core Viewpoint - The company plans to utilize idle self-owned funds for cash management, with a limit of up to RMB 200 million, focusing on low-risk financial products to enhance fund efficiency and returns for shareholders [3][4][19]. Cash Management Overview - Cash management investment types are limited to high safety, good liquidity, and low-risk financial products, including but not limited to structured deposits, principal-protected financial products, and fixed-income securities [2][7]. - The cash management limit is set at no more than RMB 200 million, including the amount itself [3][5]. - The cash management period is valid for 12 months from the date of board approval [6]. Decision-Making Process - The board of directors approved the cash management proposal during the 21st meeting of the 9th board on January 20, 2026, with a unanimous vote of 5 in favor [9][19]. - The board has authorized the general manager's office to make investment decisions within the approved limit and duration [4][8]. Purpose and Impact - The purpose of cash management is to effectively utilize idle funds while ensuring the safety of operational funds, thereby increasing returns and creating more value for the company and its shareholders [4][13]. - The cash management activities will not affect the company's daily operations or main business activities, and are expected to improve fund efficiency and yield [13][19]. Risk Control Measures - The company will select suitable financial products based on safety, duration, and yield, ensuring that cash management does not impact normal operations [11]. - A cash management ledger will be established to track the progress of cash management products, with timely measures taken to control investment risks if necessary [11][12].

证券代码：601865 证券简称：福莱特 公告编号：2026-002 一、审议并通过了《关于2025年度日常关联交易执行情况及2026年度日常关联交易预计的议案》 同意公司2025年度日常关联交易执行情况及2026年度日常关联交易预计事项。本议案在提交本次董事会 审议前，已经公司第七届董事会独立董事专门会议第五次会议及第七届董事会2026年第一次审计委员会 审议通过。 关联董事阮洪良先生、姜瑾华女士、阮泽云女士回避了本议案的表决。 表决结果：同意6票、反对0票、弃权0票。 （具体内容详见上海证券交易所网站http://www.sse.com.cn） 本议案尚需提交公司股东会审议。 转债代码：113059 转债简称：福莱转债 福莱特玻璃集团股份有限公司 第七届董事会第十四次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 福莱特玻璃集团股份有限公司（以下简称"公司"）于2026年1月15日以电子邮件及电话的方式向公司全 体董事及高级管理人员发出了召开第七届董事会第十四次会议的通知，并于2026年1月21日在公司会议 ...

Core Viewpoint - The announcement details the expected daily related transactions for 2026 by Youcare Pharmaceutical Group Co., Ltd, which are based on normal business operations and market prices, ensuring no impact on the company's independence or shareholder interests [2][3][30]. Group 1: Daily Related Transactions Overview - The total expected amount for daily related transactions in 2026 is estimated at 241.56 million RMB [3]. - The board of directors, excluding related directors, unanimously approved the proposal for these transactions [3][4]. - Independent directors confirmed that the transactions are necessary for the company's operations and do not harm the interests of shareholders, especially minority shareholders [3][30]. Group 2: Related Parties and Their Financials - Related parties include Anhui Hengshun Information Technology Co., Ltd, with total assets of 1.19 billion RMB and a net loss of 22.79 million RMB for 2025 [11][12]. - Beijing Yuantong Kangbai Pharmaceutical Co., Ltd reported total assets of 491.69 million RMB and a net loss of 16.34 million RMB for 2025 [13][14]. - Other related parties include Beijing Kaicheng Yichuang Technology Co., Ltd, with total assets of 64.70 million RMB and a net loss of 6.13 million RMB for 2025 [16][17]. Group 3: Transaction Details and Pricing Principles - The main content of the expected transactions includes sales of products, procurement of goods and services, and leasing of properties between the company and related parties [27]. - Pricing for these transactions will follow government pricing, market prices, and negotiated agreement prices to ensure fairness [28]. - The company will sign specific contracts with related parties after board and shareholder approval [29]. Group 4: Necessity and Impact of Related Transactions - The related transactions are deemed necessary for maintaining supply chain stability and improving internal management efficiency [30]. - The pricing of these transactions is considered fair and reasonable, with no significant differences from external non-related third-party prices [31]. - The volume of related transactions is low compared to the company's main business income, ensuring no dependency on related parties [32].

Core Viewpoint - The company has approved several proposals during the 23rd meeting of the third board of directors, including anticipated related party transactions for 2026, which will be submitted for shareholder approval due to the recusal of certain directors [1] Group 1: Proposals Approved - The proposal regarding expected related party transactions for the year 2026 was approved with 7 votes in favor, requiring further shareholder meeting approval due to the recusal of Chairman Shen Qingfang and others [1] - The proposals for applying for financial derivatives trading limits and bank credit limits were both approved with 9 votes in favor [1] Group 2: Loan Approvals - The company and its subsidiaries have agreed to provide loan limits to its controlling subsidiaries, with the company providing 303 million yuan, Hongqi Sheng Precision providing 100 million yuan, and Pengding International providing 40 million USD [1] - The loan period is set from January 1, 2026, to December 31, 2026, with interest rates not lower than the prevailing market rates [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 一、召开会议的基本情况 （一）股东会届次：2026年第一次临时股东会 （二）股东会的召集人：董事会 金陵药业股份有限公司 （四）会议时间： 1、现场会议时间：2026年2月5日14:30 关于召开2026年第一次临时股东会的通知 （三）本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 证券代码：000919 证券简称：金陵药业 公告编号：2026-004 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 ■ 2、网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2026年2月5日9:15-9:25，9:30- 11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2026年2月5日9:15至15:00 的任意时间。 （五）会议的召开方式：现场表决与网络投票相结合。 （六）会议的股权登记日：2026年1月30日 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 股票简称：北方国际 股票代码：000065 公告编号：2026-005 北方国际合作股份有限公司 九届十七次董事会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大遗 漏。 北方国际合作股份有限公司（以下简称"公司"或"北方国际"）九届十七次董事会会议通知已于2026年1 月15日以电子邮件和传真方式送达公司全体董事。本次会议于2026年1月20日以现场会议表决形式召 开，应参与审议表决的董事9名，实际参与审议表决的董事9名。因公司董事长暂时空缺，经过半数董事 推举，本次会议由董事谢兴国主持。会议召开程序符合《公司法》及《公司章程》的有关规定，会议合 法有效。经全体参会董事审议： 一、会议审议通过了关于《选举公司第九届董事会董事长》的议案 表决结果：同意9票，反对0票，弃权0票。 因工作调动，原公司董事长纪巍先生于2026年1月4日申请辞去公司第九届董事会董事长、董事、董事会 战略投资与ESG委员会主任委员的职务。 董事会拟聘任董事长马卫国先生为公司董事会战略投资与ESG委员会委员，并担任主任委员。任期自董 事会审 ...